Close menu




April 25th, 2025 | 07:20 CEST

US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: pexels.com

The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , PFIZER INC. DL-_05 | US7170811035 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619

Table of contents:


    US biotech association NSCEB: Bright minds must be bold

    The US has always been important for research and development. Leading minds from all over the world spend at least a few semesters in the States. Many stay or move there later. The reason: The research opportunities are diverse, the country has always been considered a cultural melting pot, and salaries for researchers in the US are unimaginable in countries such as Germany. Handelsblatt recently reported that at the University of California alone, there are 168 researchers with annual salaries ranging from USD 1 to 3.4 million. In Germany, scientists are paid according to collective agreements, and the opportunities to supplement their income are limited. Only the most idealistic among the best in their field are satisfied with a salary grade of W3, which ranges from EUR 7,500 to 9,160 per month.

    But when the freedom of research is threatened, discontent grows – even in the US, the biotech mecca of the world. In March, historian Timothy Snyder turned his back on Yale and moved to Toronto, Canada. Now, NSCEB Commissioner Ro Khanna is emphasizing the importance of a functioning research landscape for the development of the US: "*We must encourage the best and brightest minds in biotechnology to be bold. American ingenuity is being stifled by outdated regulations in this sector. *Only Congress can open the door to a biotech future led by the US."** Khanna even brings up the growing rivalry with China – it seems like an attempt to align the biotech association's mission with the Trump administration's agenda.

    Brain drain in the US: Are Israel, Canada, Australia, and the UK benefiting?

    And how are major industry representatives responding? After Matthew Memoli, acting director of the National Institutes of Health (NIH), requested a comprehensive list of all NIH-funded research projects related to mRNA technology, experts fear cuts in mRNA research. So far, major industry players such as BioNTech and Pfizer have not responded to the cuts and impending restrictions on mRNA research in the US with public criticism or political statements. Instead, both companies are continuing their development programs in the field of mRNA-based vaccines and continue to communicate positive study results and the next steps in research and development. Regional diversification, present at both Pfizer and BioNTech, should also help justify a wait-and-see approach for now.

    However, if the US scientific community remains under pressure, this is likely to be reflected in a lack of investment. Biotechnology companies from Switzerland, Canada, Australia, and Israel could benefit from such a development and attract more capital. At the German Biotech Days, which took place in early April in Heidelberg, interest groups were already promoting biotech destinations outside the US. An exciting industry representative is London-based company Vidac Pharma, which also has a branch in Israel. Vidac Pharma focuses on the development of innovative oncological and onco-dermatological therapies. The central research approach is to target the abnormal metabolism of cancer cells in order to normalize it and stop their proliferation.

    Vidac Pharma scores with promising candidates and Prof. Herzberg

    The two most important products are an ointment (VDA-1102) for an early form of skin cancer and cutaneous T-cell lymphoma, and the active ingredient VDA-1275, which targets solid tumors and has shown strong synergistic effects with chemotherapeutic agents already on the market in preclinical studies. The Company's CEO is Prof. Max Herzberg, who is considered one of the founding fathers of the Israeli biotech industry. His charisma could help convince researchers from the US to join Vidac Pharma. Even Israel and the UK could attract bright minds. Both countries score highly with low regulation for researchers. BioNTech, for example, is deliberately pushing ahead with a cancer research program in the UK.


    The fact that established pharmaceutical and biotech companies have come under pressure since the beginning of the Trump era and that smaller stocks could benefit is also underscored by the performance of BioNTech, Pfizer, and Vidac Pharma shares over the past six months. While BioNTech and Pfizer lost 20% and 14%, respectively, Vidac Pharma's market value rose by almost 90% over the same period. The biotech world is in flux – the cards are being reshuffled. Investors should keep an eye on promising stocks that operate outside the US.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read